Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38

Benzinga · 1d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.